TARCEVA (erlotinib) is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor.
TARCEVA (erlotinib) is indicated for the following:
Non-Small Cell Lung Cancer
TARCEVA monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Results from two, multicenter, placebo-controlled, randomized, Phase 3 trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of TARCEVA with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting.
TARCEVA in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Media Articles Related to Tarceva (Erlotinib)
Adding tivantinib to standard erlotinib treatment improved outcomes for specific subgroup of patients with lung cancer
Source: Lung Cancer News From Medical News Today [2015.11.07]
Adding the investigational anticancer therapeutic tivantinib to standard erlotinibtreatment substantially increased progression-free survival for patients with advancednonsquamous non-small...
Published Studies Related to Tarceva (Erlotinib)
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients
with multiple brain metastases. 
and its direct effect on brain metastases and systemic activity... CONCLUSIONS: Our study showed no advantage in nPFS or OS for concurrent erlotinib
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing
bevacizumab therapy with or without erlotinib, after completion of chemotherapy,
with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. 
regimen with bevacizumab for advanced non-small-cell lung cancer (NSCLC)... CONCLUSION: The addition of erlotinib to bevacizumab significantly improved PFS
An evaluation of the possible interaction of gastric acid suppressing medication
and the EGFR tyrosine kinase inhibitor erlotinib. 
participants... CONCLUSION: This retrospective analysis found that the co-administration of AS
A randomized, double-blind, phase II study of erlotinib with or without sunitinib
for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). 
agents in platinum-pretreated non-small-cell lung cancer (NSCLC)... CONCLUSIONS: The addition of sunitinib to erlotinib did not significantly improve
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung
cancer patients previously treated with erlotinib or gefitinib: results of a
randomized phase IIb/III trial (LUX-Lung 1). 
in a double-blind, randomized, phase IIb/III trial (LUX-Lung 1)... CONCLUSION: In the LUX-Lung 1 trial, the addition of afatinib to BSC
Clinical Trials Related to Tarceva (Erlotinib)
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma [Completed]
This trial was originally designed and powered to compare biomarker modulation in the
neo-adjuvant setting (erlotinib versus erlotinib plus sulindac versus placebo) with clinical
response to erlotinib in the adjuvant setting. Since implementing the trial in late 2005,
The investigators have encountered significant obstacles to implementing the adjuvant
therapy phase of the trial.
- Barriers included:
1. disease recurrence
2. patient refusal to take the agent
3. patient refusal to travel to Pittsburgh for clinical evaluations.
Given the institutional challenges to implement and complete the adjuvant portion, the
investigators have decided to change the primary endpoint to a biomarker modulation
endpoint. To achieve this goal, the investigators determined that they needed 39 paired
tissue specimens (see statistical justification below).
The central hypothesis to be tested in this study is that persistent activation of parallel
and/or downstream pathways contributes to tumor progression in the setting of EGFR blockade.
While not all head and neck squamous cell carcinoma (HNSCC) patients will respond to EGFR
targeting, the optimal strategy to identify those subjects whose tumors are sensitive to
EGFR inhibition remains unknown.
The primary objective is centered around the concept of tumor biomarkers which may be
modulated by EGFR and Cox-2 inhibitors and may serve as future therapeutic targets for
therapy. To this end patients on this trial will be randomly assigned to one of three arms
to receive either Tarceva, Tarceva plus sulindac, or a placebo in the 2 week pre-operative
period. A panel of biomarkers will be obtained by biopsy prior to pre-operative therapy and
again at surgery. Biomarkers will be examined for modulation in the 2-week pre-operative
period, for group differences, for treatment effects and for further understanding of
protein signaling pathways.
Sample size for the primary objective
Modification of Statistical Design:
The primary endpoint is the difference between pre (biopsy) and post (surgery). There are 3
hypotheses of interest: (1) placebo vs erlotinib alone, (2) placebo versus erlotinib plus
sulindac, and (3) erlotinib vs erlotinib + sulindac. With a randomization in a 3: 5:5 ratio,
we have 88% power, alpha = .01 for an omnibus test to show between-group differences of 1
log exist. This requires 39 patients. Basically, 39 patients will provide the ability to
detect a one log difference between any 2 of the 3 groups in pre-post change.
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 [Terminated]
Patients that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and
either progressed while on study or discontinued due to unacceptable toxicity related to
etoposide will be allowed to participate in this study to assess the safety profile of
single-agent erlotinib in patients with recurrent or refractory pediatric ependymoma.
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) [Active, not recruiting]
The goal of this clinical research study is to find out if erlotinib given with chemotherapy
and radiation therapy can help to control Non-Small Cell Lung Cancer (NSCLC). The safety of
this combination treatment will also be studied.
Researchers will also test the tissue from your earlier biopsy to measure the levels of
epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any
link between various forms of EGFR and your response to treatment with erlotinib.
Determine the feasibility of concurrent erlotinib and chemoradiation as measured by safety
and compliance. Safety is measured by the rate of grade 3 or worse nonhematological
toxicities occurring prior to the beginning of consolidation therapy (including all
toxicities attributed to chemoradiation occurring within 90 days of the start of radiation
therapy); compliance is defined as the completion of the treatment regimen with no more than
1. Investigate associations between EGFR expression and toxicity, response, overall
survival, and progression
2. Estimate overall survival of patients on the study regimen (one and two year rates,
3. Estimate the time to disease progression of patients on the study regimen (one and two
4. Estimate the treatment response rate of patients on the study regimen (complete and
partial response rates)
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma [Completed]
The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an
inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who
are carriers of head and neck epidermoid carcinoma.
Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer [Active, not recruiting]
This study is a phase II trial of erlotinib in combination with chemoradiation in patients
with resected stage I/II adenocarcinoma of the pancreas who are candidates for adjuvant
chemoradiation. Eligible patients will receive adjuvant treatment with erlotinib 100 mg plus
Capecitabine 800 mg/m2 by mouth twice daily (PO BID) (5 days on/2 days off regimen) and
External Beam Radiation Therapy (EBRT) at doses of 50. 4 Gy in 28 fractions after
pancreatectomy (dosing for capecitabine and erlotinib was amended after considering the
toxicity profile of the first 6 patients). Approximately 4-8 weeks after the conclusion of
chemoradiation, it is recommended patients will continue treatment with 4 cycles of
gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg.
Reports of Suspected Tarceva (Erlotinib) Side Effects
Disease Progression (66),
Neoplasm Malignant (66),
Incorrect Dose Administered (53),
Decreased Appetite (52),
Dyspnoea (52), more >>
Page last updated: 2015-11-07